Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

The shares underperformed the S&P 500 in the latest session, while analysts’ consensus calls for higher earnings and revenue in the upcoming report.

Zacks points to growth across several businesses, while pricing pressure and weaker Medical-Surgical results remain risks for the distributor.

The healthcare distributor raised earnings guidance after a strong first quarter and outlined how a $2.25 billion deal will deepen its oncology platform.